Dr. John H. Vu, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 322
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME124795 -
Internal Medicine Physician
FL license ME124795
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center - Jacksonville Jacksonville, FL
- Baptist Medical Center Beaches Jacksonville Beach, FL
- Baptist Medical Center - Nassau Fernandina Beach, FL
Medical groups
- Baptist MD Anderson Cancer Physicians Inc (119 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 322
- Services billed
- 970
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 417 | 222 |
| Established patient office or other outpatient visit, 20-29 minutes | 183 | 146 |
| Established patient office or other outpatient visit, 40-54 minutes | 103 | 69 |
| New patient office or other outpatient visit, 45-59 minutes | 47 | 47 |
| New patient office or other outpatient visit, 60-74 minutes | 30 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Jacksonville, FL | 92 |
| Ondansetron Hcl Other prescribers in Jacksonville, FL | 88 |
| Tagrisso (osimertinib mesylate) | 70 |
| Levothyroxine Sodium Other prescribers in Jacksonville, FL | 62 |
| Eliquis (apixaban) Other prescribers in Jacksonville, FL | 61 |
| Gabapentin Other prescribers in Jacksonville, FL | 50 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Jacksonville, FL | 45 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Jacksonville, FL | 45 |
| Prednisone Other prescribers in Jacksonville, FL | 44 |
| Oxycodone Hcl Other prescribers in Jacksonville, FL | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 6 payments worth $437 in total to this clinician.
| Caris Mpi, Inc. | $125 |
|---|---|
| Immunocore Limited | $116 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $110 |
| AstraZeneca Pharmaceuticals LP | $48.86 |
| Celgene Corporation | $19.06 |
| Novocure Inc. | $18.56 |
| Food and Beverage | $437 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $158,861 in research payments for these studies, mostly to the institutions running them.
- A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - A phase 12 randomized doubleblinded study to evaluate the safety tolerability and immunogenicity of modified rna vaccine candidates against influenza and COVID19 in healthy individuals
Pfizer Inc. - A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Merck Sharp & Dohme LLC - A phase 3 study to evaluate the safety tolerability and immunogenicity of a respiratory syncytial virus rsv prefusion f subunit vaccine in adults 60 years of age and older
Pfizer Inc. - A Phase 4, single-arm, open-label clinical study of pembrolizumab MK-3475 to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent,metastatic head and neck sq…
Merck Sharp & Dohme LLC - Study name not reported
Organon Llc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.